Assisted circulation:: experience with the Novacor® left ventricular assist system
Assisted circulation:: experience with the Novacor® left ventricular assist system
复制标题
DOI：
10.1586/17434440.4.6.769
复制
发表时间：
2007-11-01
影响因子：
3.1
通讯作者：
Elefteriades, John A.
中科院分区：
文献类型：
--
作者：
Farkas, Emily A.;Elefteriades, John A.
心脏衰竭的外科治疗是一个相对年轻的解决方案，这个问题可以追溯到第一王朝。尽管几个世纪以来多学科的医疗和技术取得了巨大的进步，但2006年美国每天仍有近2000人死于心血管疾病，平均每35秒就有一人死亡，死亡人数超过了接下来的四个主要死因的总和。2007年，每30名女性死亡者中就有一人死于乳腺癌，每2.6人中就有一人死于心血管疾病。心力衰竭的患病率在美国每年高达500万，在欧洲为650万。此外，根据国家心脏，血液和肺研究所心脏研究的44年随访，65岁以下患有心力衰竭的80%男性和70%女性将在8年内死亡。本文的重点将是回顾Novaco左心室辅助系统的历史和未来，因为它与衰竭的心脏有关;创新者，研究人员，工程师和外科医生如何走到一起，为不可思议的医疗问题提供手术解决方案。
Surgical therapy for the treatment of heart failure is a relatively young solution to a problem that has overwhelmed civilizations dating back to the First Dynasty. Despite centuries of enormous multidisciplinary medical and technological advance, nearly 2000 people in the USA died of cardiovascular disease every day in 2006, averaging one death every 35 seconds, and claiming more lives than the next four leading causes of death combined. In 2007, one in 30 female deaths will be from breast cancer, while one in 2.6 will be from cardiovascular disease. The prevalence of heart failure in our population is a staggering 5 million in the USA and 6.5 million in Europe per year. Furthermore, based on the 44-year follow-up of the National Heart, Blood, and Lungs Institute Framingham Heart Study, 80% of men and 70% of women under the age of 65 years who have heart failure will die within 8 years. The focus of this article will be to review the history and future of the Novaco (R) Left Ventricular Assist System as it relates to the failing heart; the story of how the innovator, the researcher, the engineer and the surgeon have come together to offer a surgical solution to a medical problem of inconceivable scope.